Interleukin 2 targeted therapy in inflammatory bowel disease

Comment

S Yarkoni et al. Gut. 2009 Dec.

. 2009 Dec;58(12):1705-6.

doi: 10.1136/gut.2008.175182.

No abstract available

Comment on

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS. Van Assche G, et al. Gut. 2006 Nov;55(11):1568-74. doi: 10.1136/gut.2005.089854. Epub 2006 Apr 7. Gut. 2006. PMID: 16603634 Free PMC article. Clinical Trial.
Therapeutic potency of IL2-caspase 3 targeted treatment in a murine experimental model of inflammatory bowel disease.
Shteingart S, Rapoport M, Grodzovski I, Sabag O, Lichtenstein M, Eavri R, Lorberboum-Galski H. Shteingart S, et al. Gut. 2009 Jun;58(6):790-8. doi: 10.1136/gut.2008.153981. Epub 2008 Oct 31. Gut. 2009. PMID: 18978179